print.pipe: Print information regarding a trial conducted using the...

In pipe.design: Dual-Agent Dose Escalation for Phase I Trials using the PIPE Design

Description

Print method for a trial or series of trials conducted using a pipe.design model.

Usage

## S3 method for class 'pipe'
print(x, ...)
## S3 method for class 'pipe.sim'
print(x, pi = x$pi, 
  cut.points = unique(c(0,pmin(1,pmax(0,seq(x$theta-0.15,x$theta+0.15,by=0.1))),1)), 
  digits = 1, print = TRUE, ...)

Arguments

x	An object of class "pipe" or "pipe.sim" as returned by pipe.design
pi	A matrix with rows denoting levels of drug A and columns denoting levels of drug B. Each element gives the true probability of the outcome (dose-limiting toxicity) for that dose combination. If omitted then the true probabilities of the outcome will be taken from that used when creating the x object.
cut.points	Cutpoints of toxicity for which the operating characteristics are to be categorised. Default is [0,x$theta-0.1) [x$theta-0.1,x$theta+0.1) [x$theta+0.1,1]
digits	The number of decimal places to print the operating characteristics
print	If TRUE then the experimentation and recommendation percentages are printed to the output
...	Further arguments passed to or from other methods

Details

If a single trial is conducted, then the print function currently produces summary information about the data observed, current best estimate of the MTC and the upper toxicity constraint contour. If a simulation study is conducted, then the following operating characteristics are printed:

Experimentation percentages

Percentage of patients recruited to each true region of toxicity (as specified by cut.points), across the simulated trials

Recommendation percentages

Percentage of times that recommend doses lie within each true region of toxicity (as specified by cut.points). As more than one dose combination can be recommended in any trial, the denominator is the total number of recommended phase II doses over the simulations

Percentage of times a trial recommends k doses for Phase II

Provides the percentage of time that each trial recommends 0, 1, ..., k doses for Phase II experimentation. 0 doses indicates that the trial stopped early and recommended no doses.

Author(s)

Michael Sweeting [e-mail]

References

Mander A.P., Sweeting M.J. A product of independent beta probabilities dose escalation design for dual-agent phase I trials. Statistics in Medicine (2015) 34(8): 1261–1276.

See Also

pipe.design, plot.pipe

pipe.design documentation built on May 2, 2019, 12:39 a.m.